Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoshiyuki Ohsugi

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Journal of Translational Autoimmunity|August 4, 2020
The immunobiology of humanized Anti-IL6 receptor antibody: From basic research to breakthrough medicineYoshiyuki Ohsugi
Biological & Pharmaceutical Bulletin|November 6, 2007
Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseasesYoshiyuki Ohsugi
Expert Opinion on Biological Therapy|April 15, 2008
The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritisYoshiyuki Ohsugi, Tadamitsu Kishimoto
Endocrine, Metabolic & Immune Disorders Drug Targets|March 17, 2015
IL-6 as a target in inflammationMisato Hashizume, Yoshiyuki Ohsugi
Open Access Rheumatology : Research and Reviews|February 25, 2011
Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritisMasahiko Mihara, Yoshiyuki Ohsugi, Tadamitsu Kishimoto
Biofactors (Oxford, England)|March 26, 2009
Evidence for the role of Th17 cell inhibition in the prevention of autoimmune diseases by anti-interluekin-6 receptor antibodyMasahiko Mihara, Yoshiyuki Ohsugi, Tadamitsu Kishimoto
Expert Opinion on Biological Therapy|June 7, 2005
The therapy of autoimmune diseases by anti-interleukin-6 receptor antibodyMasahiko Mihara, Norihiro Nishimoto, Yoshiyuki Ohsugi
Autoimmunity Reviews|August 22, 2006
B cells and autoimmune liver diseasesYuki Moritoki, Zhe-Xiong Lian, Yoshiyuki Ohsugi, et al.
International Immunopharmacology|August 17, 2005
Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine familyMasahiko Mihara, Keiko Kasutani, Makoto Okazaki, et al.
Autoimmunity|March 21, 2009
Effects of interleukin-6 blockade on the development of autoimmune thyroiditis in nonobese diabetic miceKouki Mori, Katsumi Yoshida, Masahiko Mihara, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Journal of Translational Autoimmunity|August 4, 2020
The immunobiology of humanized Anti-IL6 receptor antibody: From basic research to breakthrough medicineYoshiyuki Ohsugi
Biological & Pharmaceutical Bulletin|November 6, 2007
Recent advances in immunopathophysiology of interleukin-6: an innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseasesYoshiyuki Ohsugi
Expert Opinion on Biological Therapy|April 15, 2008
The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritisYoshiyuki Ohsugi, Tadamitsu Kishimoto
Endocrine, Metabolic & Immune Disorders Drug Targets|March 17, 2015
IL-6 as a target in inflammationMisato Hashizume, Yoshiyuki Ohsugi
Open Access Rheumatology : Research and Reviews|February 25, 2011
Tocilizumab, a humanized anti-interleukin-6 receptor antibody, for treatment of rheumatoid arthritisMasahiko Mihara, Yoshiyuki Ohsugi, Tadamitsu Kishimoto
Biofactors (Oxford, England)|March 26, 2009
Evidence for the role of Th17 cell inhibition in the prevention of autoimmune diseases by anti-interluekin-6 receptor antibodyMasahiko Mihara, Yoshiyuki Ohsugi, Tadamitsu Kishimoto
Expert Opinion on Biological Therapy|June 7, 2005
The therapy of autoimmune diseases by anti-interleukin-6 receptor antibodyMasahiko Mihara, Norihiro Nishimoto, Yoshiyuki Ohsugi
Autoimmunity Reviews|August 22, 2006
B cells and autoimmune liver diseasesYuki Moritoki, Zhe-Xiong Lian, Yoshiyuki Ohsugi, et al.
International Immunopharmacology|August 17, 2005
Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine familyMasahiko Mihara, Keiko Kasutani, Makoto Okazaki, et al.
Autoimmunity|March 21, 2009
Effects of interleukin-6 blockade on the development of autoimmune thyroiditis in nonobese diabetic miceKouki Mori, Katsumi Yoshida, Masahiko Mihara, et al.
Pageof 3